Elixinol Wellness (ELLXF) AI Stock Analysis
Elixinol Wellness
(Other OTC:ELLXF)
No summary available
Elixinol Wellness (ELLXF) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $1.59M
- Dividend Yield
- ―
- Average Volume (3M)
- 1,000
- Price to Earnings (P/E)
- -0.6
- Beta (1Y)
- -1.54
- Revenue Growth
- -0.51%
- EPS Growth
- -19.30%
- Country
- US
- Employees
- 15
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Elixinol Wellness Business Overview & Revenue Model
Company Description
Elixinol Wellness Limited, an entity established in 2017 and headquartered in Sydney, Australia, operates internationally through its subsidiaries. The company is primarily involved in the manufacturing and global distribution of a wide array of hemp...
Elixinol Wellness Earnings Call Summary
The call communicated meaningful operational progress: a clear shift to higher-margin channels (e-commerce up to 38%), significant cost structure reduction (~30% in Q4 vs prior year), Q4 profitability and positive operating cash flow, strong D2C momentum (Healthy Chef e-commerce +42% YoY) and product innovation poised to capture market trends. However, challenges remain including modest full-year revenue growth (3.6% YoY), a small absolute revenue base (~$15.5M), supermarket channel pressures for niche SKUs, and regulatory uncertainty in the U.S. CBD business. On balance, the operational improvements and trajectory toward sustainable profitability outweigh the outstanding strategic and market risks, but execution and regulatory clarity will be important near-term drivers.
Q4-2025 Updates
Positive Updates
Negative Updates
Company Guidance
Management guided FY26 around four pillars — operational momentum, cost efficiency, building a growth foundation and targeted M&A — with the aim of maintaining a structurally lower OpEx run‑rate after cutting the operating cost base by ~30% in Q4 vs Q4 FY24 and delivering Q4 positive EBITDA (slightly better than break‑even) and positive underlying operating cash flow; they completed a two‑tranche $2.5m capital raise and will review capital management at the May AGM. The company will prioritize higher‑margin D2C and e‑commerce (e‑commerce grew from 21% to 38% of revenue in 2025; Healthy Chef e‑commerce +42% YoY in Q4) while reducing low‑margin bulk (from 24% to 14%), leveraging FY25 revenue of $15.5m and a Q4 exit run‑rate of $4.1m (quarterly revenue ranged ~$3–4m) with contracted hemp volumes up for 2026. Management also signalled near‑term actions — pursuing value‑accretive acquisitions, keeping U.S. CBD options open pending regulatory clarity in 2–3 months, and driving product launches (Healthy Chef Metabolic Burn and protein water, plus Mt Elephant NPD into Coles in May) to capture large market opportunities (Australia wellness ~$160bn today to >$300bn by 2033 at ~7% growth, functional foods ~$10.5bn, protein market to $1.1bn by 2034) and narrow the current valuation gap (~0.3x revenue vs peers 1–1.5x).
Elixinol Wellness Peers Comparison
Overall Rating
AU:VLS82Outperform
AU:CAN53Neutral
AU:LGP53Neutral
AU:VIT44Neutral
AU:PKP39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:VLS | 82Outperform | AUD 147.70M | 13.70 | 19.91% | 5.29% | 12.19% | 22.36% |
| AU:CAN | 53Neutral | AUD 8.30M | 0.30 | 64.70% | ― | -24.22% | ― |
| AU:LGP | 53Neutral | AUD 49.68M | -13.04 | -1.67% | ― | 15.21% | -141.82% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:VIT | 44Neutral | AUD 13.25M | -2.98 | -9.80% | ― | 5.74% | -222.22% |
| AU:PKP | 39Underperform | AUD 21.43M | -5.07 | 4388.00% | ― | -19.73% | 50.34% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ELLXF | Elixinol Wellness Ltd | 0.01 | 0.00 | 0.00% | |
| AU:CAN | Cann Group Ltd. | 0.01 | -0.00 | -9.09% | |
| AU:VLS | Vita Life Sciences Limited | 2.74 | 0.47 | 20.76% | |
| AU:LGP | Little Green Pharma Ltd. | 0.06 | -0.07 | -53.85% | |
| AU:PKP | Althea Group Holdings Ltd. | 0.02 | -0.01 | -23.81% | |
| AU:VIT | Cronos Australia Ltd. | 0.02 | -0.04 | -67.74% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.